Custom polyclonal antibody production: choosing the host and the immunogen
A polyclonal antiserum is a population of antibodies against many epitopes, which makes it sensitive, tolerant of a denatured target, and finite. That finiteness is the decision people underweight: when the animal is gone, the reagent is gone. This page covers how a project is specified, what each stage delivers, and what has to be true before the serum is used for anything that matters.
- the conventional immunisation to final bleed cycle
- 70-90 days
- the NIH policy the animal work is conducted under
- PHS Policy
- the Animal Welfare Act behind the provider's facility registration
- AWA
Figures in this panel are the conventional project length and the animal welfare instruments a provider's facility operates under, named from the policies themselves and linked in the sources below. They are identifiers, not prices: BioBricks publishes verified prices for synthesis services only, and does not imply an antibody price index it has not measured.
- 4 vendor service pages verifiedevery figure matched verbatim to the vendor's page
- Quoted and dated, never estimatedlast verification pass 2026-08-24
- 1 service classes coveredeach with measured search demand behind it
Staging the project
- Choose the host by phylogenetic distance and volume needed. The host must see the antigen as foreign, so a target conserved between your species and the host gives a poor response. Rabbits give a good response and a useful serum volume; larger hosts give far more serum for a reagent that will be used for years; mice give little and are usually a route to a monoclonal instead.
- Design the immunogen, and conjugate it if it is small. A peptide under roughly ten kilodaltons will not raise a response alone and must be coupled to a carrier protein. Choose a peptide from an exposed, non-conserved region, and check it against the proteome so the serum does not recognise half the lysate.
- Fix the schedule and the bleeds in the contract. A standard programme is a primary immunisation with boosts every two to three weeks and test bleeds through a seventy to ninety day cycle. Agree what happens if titre is low at the first test bleed, because that decision point is where projects either recover or drift.
- Decide the purification before the serum arrives. Whole serum is cheapest and has the most background. Protein A or G gives total immunoglobulin. Antigen affinity purification gives the specific fraction and is what most applications actually need. The right answer depends on the application and it is much cheaper to specify than to add later.
- Validate against a negative that should be negative. Preimmune serum from the same animal, and a sample lacking the target, are the two controls that separate a specific reagent from a hopeful one. Both belong in the deliverable rather than in a later experiment.
Checking the provider's animal welfare position
Ask for the facility's registration and assurance status, the institutional committee that approved the protocol, and the adjuvant and route used. These are straightforward questions for a reputable provider and the answers are documents, not assurances.
Where work will be published or used to support a submission, that documentation is likely to be requested later. Collecting it at the point of order costs nothing; reconstructing it afterwards is sometimes impossible.
Making a finite reagent last
Aliquot on arrival, record the volume, and titrate properly so the working dilution is the most dilute that works. A serum used at twice the necessary concentration lasts half as long for no benefit.
Keep a reserve of the original unpurified serum. If a purification goes wrong or an application needs a different fraction later, the reserve is the only thing that makes that recoverable.
What to do when the animal is exhausted
Plan the transition before the last aliquot. Options are a new animal with the same immunogen, which gives a different serum that has to be revalidated, or converting to a recombinant reagent by cloning the variable regions from B cells while the animal is available.
The recombinant route is the only one that makes the reagent permanent, and it has to be decided while the animal is alive. That timing is the single most common regret in polyclonal projects.
Polyclonal antibodies production, and the herd it comes from
A polyclonal antiserum is a population of antibodies from one animal's response, so the animal is part of the reagent. Two rabbits immunised with the same antigen give different sera, and the serum runs out; that is the whole practical difference from a monoclonal, and it is why the bleed volume and whether the animal will be boosted again belong in the order.
What to specify beyond the antigen: the host species (which has to differ from the sample species and from any other primary in the panel), whether an affinity purification against the antigen is included, and what you get at the end. Ask for the serum as well as the purified fraction if the budget allows, because a purification can be repeated from serum and cannot be undone.
rabbit polyclonal antibodies and what the host gives
rabbit polyclonal antibodies are the default for a new target because the rabbit immune system gives high affinity responses to small antigens and a useful serum volume, which is why most catalogue polyclonals are rabbit raised. The consequence is that a rabbit primary needs an anti-rabbit secondary and cannot be used beside another rabbit antibody without a cross adsorbed reagent.
A klh antibody and the carrier a peptide is coupled to
Keyhole limpet haemocyanin is the usual carrier for a short peptide immunogen, so a klh antibody in a catalogue is either a reagent against the carrier itself or a polyclonal raised against a peptide conjugated to it. The distinction matters because anti-carrier antibodies are a large part of the serum and are removed by affinity purification against the peptide.
An anti bsa antibody and why it exists
Bovine serum albumin is used as a blocking agent, a carrier and a stabiliser, so an anti bsa antibody is bought either to detect the carrier in a conjugate or to investigate background in an assay blocked with it. Its presence in almost every buffer is what makes it a common source of unexplained signal, and switching the blocker is the diagnostic step.
A bsa antibody used as a control reagent
A bsa antibody serves as a positive control for a detection system, since the antigen is cheap and can be coated at a known density, which is how a secondary and a substrate are checked independently of the experiment. It also detects albumin carryover in a purification. For an immunogen conjugate, an antibody against the carrier is what proves coupling happened.
A ythdf1 antibody and targets with no proven clone
A ythdf1 antibody reports a reader of a methylated base on messenger RNA, and it is the kind of target where commercial clones are thin, which is when a custom polyclonal is worth producing. The peptide chosen has to avoid the region shared with the other readers in the family, or the serum will see all of them.
A ppara antibody and the isoform question
A ppara antibody reports one of three related nuclear receptors, so the immunogen has to come from a region the other two do not share, which is exactly the design decision a custom production run makes explicitly. A tissue with a known expression gradient is the control that shows the serum is specific rather than merely reactive.
Common questions
- How long does custom polyclonal antibody production take?
- Typically seventy to ninety days from immunisation to a final bleed, plus purification. Peptide synthesis and carrier conjugation add a few weeks at the front, and a poor first response can add a whole boost cycle.
- Why choose rabbit polyclonal antibody production?
- Rabbits raise a strong response to most mammalian targets, give a usable serum volume, and there is a very wide range of anti-rabbit secondary reagents available. For most laboratory applications it is the default for good reasons.
- Polyclonal or monoclonal?
- Polyclonal for sensitivity, for denatured targets and for immunoprecipitation, and where a finite supply is acceptable. Monoclonal where the reagent must be identical for years, where specificity has to be exact, or where the assay will be validated once and run indefinitely.
- Do I own the antigen and the serum?
- Only if the contract says so. Ownership of the immunogen, the serum, any residual and the right to resell are separate points, and providers differ. Settle them before work starts.
Get a shortlist for your project
Browse by service class
Sources
Cite or embed this figure
The median advertised gene synthesis price per base pair in the US research synthesis services market was $0.11 in August 2026, across 4 verified vendor service pages recorded in BioBricks Synthesis Price Index.
Cite as: "BioBricks Synthesis Price Index", updated 2026-08-24, https://biobricks.org/custom-polyclonal-antibody-production/.